LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 98

Search options

  1. Article ; Online: Impacts of gait freeze on quality of life in Parkinson's disease, from the perspectives of patients and their carers.

    Cronin, Padraig / Collins, Lucy M / Sullivan, Aideen M

    Irish journal of medical science

    2024  

    Abstract: Background: The World Health Organisation (WHO) reports that morbidity and mortality due to Parkinson's disease (PD) are increasing faster than for other neurodegenerative conditions. People with Parkinson's (PwP) present with a variety of motor ... ...

    Abstract Background: The World Health Organisation (WHO) reports that morbidity and mortality due to Parkinson's disease (PD) are increasing faster than for other neurodegenerative conditions. People with Parkinson's (PwP) present with a variety of motor symptoms, such as tremor, bradykinesia, and rigidity. Freezing of gait (FoG) is a significant motor symptom that manifests as temporary episodes of inability to move one's feet, despite the intention to walk.
    Aims: This study examined the impact of FoG on quality of life (QoL) within an Irish cohort of PwP, from the perspectives of both PwP and their carers, using validated questionnaires that had been adapted for online use.
    Methods: PwP and their carers were recruited by outreach to the Irish Parkinson's Community. Anonymous online questionnaires were distributed, which combined a demographic survey with several clinically validated surveys, including Freezing of Gait Questionnaire (FoG-Q), Parkinson's Disease Questionnaire 8 (PDQ-8), and Parkinson's Disease Carer Questionnaire (PDQ-C).
    Results: There was a strong correlation (p < 0.001) between severity of FoG and lower QoL among PwP. Significant correlation was also found between FoG severity and several motor symptoms, such as postural instability and difficulty with balance, and non-motor symptoms, such as cognitive changes and pain/discomfort. FoG severity correlated with disease progression. Significant correlation was also found between FoG and symptoms, as assessed from the perspective of the patients' carers.
    Conclusions: This study shows that FoG is a significant detriment to the QoL of PwP, from the perspectives of patients and carers. This method of assessing FoG and QoL using online questionnaires has potential to enhance the reach and flexibility of this type of research. These findings will inform future studies on larger cohorts and highlight unmet clinical needs in PwP.
    Language English
    Publishing date 2024-04-19
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 390895-1
    ISSN 1863-4362 ; 0021-1265
    ISSN (online) 1863-4362
    ISSN 0021-1265
    DOI 10.1007/s11845-024-03673-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Neuronal Signaling

    Sullivan, Aideen M / Stanford, S Clare

    Neuronal signaling

    2021  Volume 5, Issue 1, Page(s) NS20210007

    Abstract: The inaugural Editor-in-Chief ... ...

    Abstract The inaugural Editor-in-Chief of
    Language English
    Publishing date 2021-02-08
    Publishing country England
    Document type Editorial
    ISSN 2059-6553
    ISSN (online) 2059-6553
    DOI 10.1042/NS20210007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Neuronal Signaling

    Sullivan, Aideen M

    Neuronal signaling

    2016  Volume 1, Issue 1, Page(s) NS20160025

    Abstract: There have been a number of advances in our knowledge of neuronal communication in processes involved in development, functioning and disorders of the nervous system. This progress has prompted the Biochemical Society to ... ...

    Abstract There have been a number of advances in our knowledge of neuronal communication in processes involved in development, functioning and disorders of the nervous system. This progress has prompted the Biochemical Society to launch
    Language English
    Publishing date 2016-10-18
    Publishing country England
    Document type Editorial
    ISSN 2059-6553
    ISSN (online) 2059-6553
    DOI 10.1042/NS20160025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.

    Giles Doran, Conor / Wilson, Fionnuala / Goulding, Susan R / Mazzocchi, Martina / Collins, Louise M / Sullivan, Aideen M / O'Keeffe, Gerard W

    Movement disorders : official journal of the Movement Disorder Society

    2023  Volume 38, Issue 6, Page(s) 1115–1116

    MeSH term(s) Humans ; Glial Cell Line-Derived Neurotrophic Factor Receptors ; Parkinson Disease ; Glial Cell Line-Derived Neurotrophic Factor ; Computational Biology ; Proto-Oncogene Proteins c-ret/genetics
    Chemical Substances Glial Cell Line-Derived Neurotrophic Factor Receptors ; Glial Cell Line-Derived Neurotrophic Factor ; RET protein, human (EC 2.7.10.1) ; Proto-Oncogene Proteins c-ret (EC 2.7.10.1)
    Language English
    Publishing date 2023-07-20
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 607633-6
    ISSN 1531-8257 ; 0885-3185
    ISSN (online) 1531-8257
    ISSN 0885-3185
    DOI 10.1002/mds.29443
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Editorial: The Role of Stem Cells, Epigenetics and MicroRNAs in Parkinson's Disease.

    Hegarty, Shane V / Green, Holly F / Niclis, Jonathan / O'Keeffe, Gerard W / Sullivan, Aideen M

    Frontiers in neuroscience

    2020  Volume 14, Page(s) 515

    Language English
    Publishing date 2020-06-16
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2411902-7
    ISSN 1662-453X ; 1662-4548
    ISSN (online) 1662-453X
    ISSN 1662-4548
    DOI 10.3389/fnins.2020.00515
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Trophic factors for Parkinson's disease: Where are we and where do we go from here?

    Paul, Gesine / Sullivan, Aideen M

    The European journal of neuroscience

    2018  Volume 49, Issue 4, Page(s) 440–452

    Abstract: Perhaps the most important unmet clinical need in Parkinson's disease (PD) is the development of a therapy that can slow or halt disease progression. Extensive preclinical research has provided evidence for the neurorestorative properties of several ... ...

    Abstract Perhaps the most important unmet clinical need in Parkinson's disease (PD) is the development of a therapy that can slow or halt disease progression. Extensive preclinical research has provided evidence for the neurorestorative properties of several growth factors, yet only a few have been evaluated in clinical studies. Attempts to achieve neuroprotection by addressing cell-autonomous mechanisms and targeting dopaminergic neurons have been disappointing. Four different trophic factors have so far entered clinical trials in PD: glial cell line-derived growth factor, its close structural and functional analog neurturin, platelet-derived growth factor and cerebral dopaminergic neurotrophic factor. This article reviews the pre-clinical evidence for the neuroprotective and neurorestorative actions of these growth factors and discusses limitations of preclinical models, which may hamper successful translation to the clinic. We summarize the previous and ongoing clinical trials using growth factors in PD and emphasize the caveats in clinical trial design that may prevent the further development and registration of potentially neuroprotective and neurorestorative treatments for individuals suffering from PD.
    MeSH term(s) Animals ; Humans ; Nerve Growth Factors/metabolism ; Neuregulin-1/metabolism ; Neuroprotection/physiology ; Neurturin/metabolism ; Parkinson Disease/metabolism ; Platelet-Derived Growth Factor/metabolism
    Chemical Substances CDNF protein, human ; Nerve Growth Factors ; Neuregulin-1 ; Neurturin ; Platelet-Derived Growth Factor
    Language English
    Publishing date 2018-09-09
    Publishing country France
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 645180-9
    ISSN 1460-9568 ; 0953-816X
    ISSN (online) 1460-9568
    ISSN 0953-816X
    DOI 10.1111/ejn.14102
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Human α-synuclein overexpression upregulates SKOR1 in a rat model of simulated nigrostriatal ageing.

    Morales-Prieto, Noelia / Bevans, Rebekah / O'Mahony, Adam / Barron, Aaron / Giles Doran, Conor / McCarthy, Erin / Concannon, Ruth M / Goulding, Susan R / McCarthy, Cathal M / Collins, Louise M / Sullivan, Aideen M / O'Keeffe, Gerard W

    Aging cell

    2024  , Page(s) e14155

    Abstract: Parkinson's disease (PD) is characterised by progressive loss of dopaminergic (DA) neurons from the substantia nigra (SN) and α-synuclein (αSyn) accumulation. Age is the biggest risk factor for PD and may create a vulnerable pre-parkinsonian state, but ... ...

    Abstract Parkinson's disease (PD) is characterised by progressive loss of dopaminergic (DA) neurons from the substantia nigra (SN) and α-synuclein (αSyn) accumulation. Age is the biggest risk factor for PD and may create a vulnerable pre-parkinsonian state, but the drivers of this association are unclear. It is known that ageing increases αSyn expression in DA neurons and that this may alter molecular processes that are central to maintaining nigrostriatal integrity. To model this, adult female Sprague-Dawley rats received a unilateral intranigral injection of adeno-associated viral (AAV) vector carrying wild-type human αSyn (AAV-αSyn) or control vector (AAV-Null). AAV-αSyn induced no detrimental effects on motor behaviour, but there was expression of human wild-type αSyn throughout the midbrain and ipsilateral striatum at 20 weeks post-surgery. Microarray analysis revealed that the gene most-upregulated in the ipsilateral SN of the AAV-αSyn group was the SKI Family Transcriptional Corepressor 1 (SKOR1). Bioenergetic state analysis of mitochondrial function found that SKOR1 overexpression reduced the maximum rate of cellular respiration in SH-SY5Y cells. Furthermore, experiments in SH-SY5Y cells revealed that SKOR1 overexpression impaired neurite growth to the same extent as αSyn, and inhibited BMP-SMAD-dependent transcription, a pathway that promotes DA neuronal survival and growth. Given the normal influence of ageing on DA neuron loss in human SN, the extent of αSyn-induced SKOR1 expression may influence whether an individual undergoes normal nigrostriatal ageing or reaches a threshold for prodromal PD. This provides new insight into mechanisms through which ageing-related increases in αSyn may influence molecular mechanisms important for the maintenance of neuronal integrity.
    Language English
    Publishing date 2024-03-26
    Publishing country England
    Document type Journal Article
    ZDB-ID 2113083-8
    ISSN 1474-9726 ; 1474-9718
    ISSN (online) 1474-9726
    ISSN 1474-9718
    DOI 10.1111/acel.14155
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Exercise as therapy for Parkinson's?

    Crowley, Erin K / Nolan, Yvonne M / Sullivan, Aideen M

    Aging

    2018  Volume 10, Issue 7, Page(s) 1536–1537

    MeSH term(s) Animals ; Gene Expression Regulation ; Humans ; Male ; Parkinson Disease/etiology ; Parkinson Disease/therapy ; Physical Conditioning, Animal ; Psychomotor Performance ; Rats ; Rats, Sprague-Dawley ; Transfection ; alpha-Synuclein/administration & dosage ; alpha-Synuclein/genetics ; alpha-Synuclein/metabolism
    Chemical Substances alpha-Synuclein
    Language English
    Publishing date 2018-07-23
    Publishing country United States
    Document type Journal Article
    ISSN 1945-4589
    ISSN (online) 1945-4589
    DOI 10.18632/aging.101503
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Neurotrophic factor therapy for Parkinson's disease: past, present and future.

    Sullivan, Aideen M / O'Keeffe, Gerard W

    Neural regeneration research

    2016  Volume 11, Issue 2, Page(s) 205–207

    Language English
    Publishing date 2016-04-12
    Publishing country India
    Document type Journal Article
    ZDB-ID 2388460-5
    ISSN 1876-7958 ; 1673-5374
    ISSN (online) 1876-7958
    ISSN 1673-5374
    DOI 10.4103/1673-5374.177710
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.

    Goulding, Susan R / Anantha, Jayanth / Collins, Louise M / Sullivan, Aideen M / O'Keeffe, Gerard W

    Neural regeneration research

    2021  Volume 17, Issue 1, Page(s) 38–44

    Abstract: Parkinson's disease is the most common movement disorder worldwide, affecting over 6 million people. It is an age-related disease, occurring in 1% of people over the age of 60, and 3% of the population over 80 years. The disease is characterized by the ... ...

    Abstract Parkinson's disease is the most common movement disorder worldwide, affecting over 6 million people. It is an age-related disease, occurring in 1% of people over the age of 60, and 3% of the population over 80 years. The disease is characterized by the progressive loss of midbrain dopaminergic neurons from the substantia nigra, and their axons, which innervate the striatum, resulting in the characteristic motor and non-motor symptoms of Parkinson's disease. This is paralleled by the intracellular accumulation of α-synuclein in several regions of the nervous system. Current therapies are solely symptomatic and do not stop or slow disease progression. One promising disease-modifying strategy to arrest the loss of dopaminergic neurons is the targeted delivery of neurotrophic factors to the substantia nigra or striatum, to protect the remaining dopaminergic neurons of the nigrostriatal pathway. However, clinical trials of two well-established neurotrophic factors, glial cell line-derived neurotrophic factor and neurturin, have failed to meet their primary end-points. This failure is thought to be at least partly due to the downregulation by α-synuclein of Ret, the common co-receptor of glial cell line-derived neurorophic factor and neurturin. Growth/differentiation factor 5 is a member of the bone morphogenetic protein family of neurotrophic factors, that signals through the Ret-independent canonical Smad signaling pathway. Here, we review the evidence for the neurotrophic potential of growth/differentiation factor 5 in in vitro and in vivo models of Parkinson's disease. We discuss new work on growth/differentiation factor 5's mechanisms of action, as well as data showing that viral delivery of growth/differentiation factor 5 to the substantia nigra is neuroprotective in the α-synuclein rat model of Parkinson's disease. These data highlight the potential for growth/differentiation factor 5 as a disease-modifying therapy for Parkinson's disease.
    Language English
    Publishing date 2021-06-07
    Publishing country India
    Document type Journal Article
    ZDB-ID 2388460-5
    ISSN 1876-7958 ; 1673-5374
    ISSN (online) 1876-7958
    ISSN 1673-5374
    DOI 10.4103/1673-5374.314290
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top